Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice

BACKGROUND: The use of somatostatin analogues (SSAs) has not been formally approved in pulmonary neuroendocrine tumours (NETs) in the absence of positive controlled trials, even though it is recommended as a potential therapeutic option in recent guidelines. PATIENTS AND METHODS: We have assessed th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiesewetter, B., Mazal, P., Kretschmer-Chott, E., Mayerhoefer, M.E., Raderer, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271480/
https://www.ncbi.nlm.nih.gov/pubmed/35525183
http://dx.doi.org/10.1016/j.esmoop.2022.100478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271480/
https://www.ncbi.nlm.nih.gov/pubmed/35525183
http://dx.doi.org/10.1016/j.esmoop.2022.100478

Ejemplares similares